Designing E-Banking Cardless Transaction Services Framework for Banking Sectors in Ethiopia

E-banking cardless technologies, enable to withdraw cash from ATM without virtual or any physical card. It increases enhanced utilization of ATM banking services and improve flexibility of services to customers. The purpose of this research was to develop cardless e-banking services. The study used design Science research methodology. The study uses requirement elicitation method to identify and analyze existing system challenges then to design E-banking cardless transaction services framework. Based on the proposed framework, the software was developed that allows customer to withdraw cash from ATM machine using their mobile phone. Based on the study result, card expiration, captured, dispute and forgotten were the main challenges to the exiting ATM based banking services. All of the respondents were used Mobile and ATM services. Domain experts were evaluated both the framework and the prototype, acceptable result was found from the evaluation. The integration of ATM and Mobile banking services and the ECTS framework development can enhance utilization of E-banking services

BLOOD PRESSURE DISTRIBUTION AND HYPERTENSION IN TWO RURAL COMMUNITIES OF GONDAR REGION, ETHIOPIA

ABSTRACT: The purpose of this study was to document the distribution of blood pressures and the prevalence of hypertension in two rural communities located in the northwestern Gondar Region of Ethiopia. Based upon a systematic random sampling, 226 households (724 persons) were selected. Mean systolic and diastolic blood pressures (SBP and DBP) were calculated separately for male and female children (5 -15 years) and adults. Among male and female children the mean SBP's were 110.0 +/- 9.5 and 113.4 =/- 10.0, while the mean DBP's were 73.8 +/- 8.2 and 73.8 +/- 7.9, respectively. The difference in mean SBP's was statistically significant (p<0.05). Among adult males and females the mean SBP was 118 +/- 13.3 and 114.0 +/- 14.5, while the mean DDP was 73.5 +/- 8.2 and 72.7 +/- 9.2 respectively. The difference in mean SBP's was statistically significant (p<0.05). Blood pressure was found to rise with age. The prevalence of hypertension in children was 4.3% and in adults 2.7%. Prevalence rates were not significantly different in females and males

COVID-19 Vaccine Hesitancy and its Reasons in Addis Ababa, Ethiopia: A Cross-Sectional Study

BACKGROUND: Coronavirus disease (COVID-19) vaccine hesitancy becomes the major bottleneck to the global healthcare system in minimizing the spread of the virus. This study aimed at assessing COVID-19 vaccine hesitancy and its reasons among residents of Addis Ababa, Ethiopia. METHODS:  A community-based cross-sectional survey was conducted between May 16 to 29, 2021 in purposively selected four districts of Addis Ababa, Ethiopia. A structured questionnaire was developed and then designed on Google Forms platforms to collect data from study participants after obtaining a verbal consent form. A total of 422 study participants were included in the survey. Data were entered into Microsoft Excel and then exported to the Statistical Package for the Social Sciences (SPSS) version 25 for analysis.  RESULTS: Face masks and alcohol hand rub/ sanitizer are used by 50. 7 and 24.9% of respondents when required. COVID-19 was thought to have been generated by humans by a substantial percentage of study participants (38.2%). About half (50.7%) and 24.9% of respondents use face masks and alcohol hand rub/sanitizer always when it is required, respectively. A large number of study participants (38.2%) believed that origin of COVID-19 is man-made. Overall, 242 (57.4%) of study participants reported COVID-19 vaccine hesitancy. Fear of vaccine side effects (49.6%) was the most common reason for hesitancy. Doubt about its effectiveness (33.9%), not having enough information about the COVID-19 vaccine, preferring another way of protection, and unreliable of the vaccine (due to its short development period) were also the most frequently mentioned reasons for not receiving the COVID-19 vaccine. CONCLUSIONS: COVID-19 vaccine hesitancy rate was high in Addis Ababa, Ethiopia during the study period. Fear of side effects, doubts about its effectiveness, and not having enough information about the COVID-19 vaccine were major reasons for hesitancy. Continuous awareness creation to the community on the importance of vaccination is warranted by health professionals and healthcare cadres

Magnitude of Antiretroviral Drug toxicity in adult HIV patients in Ethiopia: A cohort study at seven teaching hospitals

Background: The introduction of antiretroviral therapy (ART) has resulted in significant mortality reduction and improvement in the quality of life. However, this has come at a cost of increased drug toxicity. The objective of this study was to assess the patterns and predictors of ART toxicity in adult HIV patients in Ethiopia.Methods: This is a prospective cohort study conducted at seven teaching hospitals between September 2009 and December 2013 involving 3921 HIV patients on ART. Adverse drug reactions (ADR) due to ART were identified based on clinical assessment and/or laboratory parameters. Multivariable random effects Poisson regression analysis was used to identify factors independently associated with toxicity.Result: ADR due to ART drugs was reported in 867 (22.1 %) of the participants; 374 (9.5%) had severe forms. About 87% of reported toxicities were limited to three organ systems – the skin, nervous system and blood. The overall incidence of ADR was 9 per 100 person years. About a third of toxicities occurred during the first six months after ART initiation with the incidence rate of 22.4 per 100 person years. Concomitant anti-tuberculosis treatment was the strongest independent predictor of toxicity.Conclusion: ADR was found to be highly prevalent in HIV patients on ART at tertiary hospitals in Ethiopia. Most of these conditions occurred early after ART initiation and in those with concomitant anti-tuberculosis treatment. Thus, routine monitoring of patients on ART should be strengthened with particular emphasis in the first 6 months. Strategies should also be devised to replace older and more toxic agents with newer and safer drugs available.Key words: HIV, ART, adverse drug reaction, incidence rate, ACM, Ethiopi

Rotavirus-associated acute diarrhea outbreak in West Shewa Zone of Oromia Regional State, Ethiopia, 2017

Introduction: rotavirus causes severe-diarrheal diseases in infants. An estimation of 138 million rotavirus-associated diarrheal cases and 215,000 deaths occur every year globally. In December 2016, West-Shewa zone in Ethiopia reported unidentified gastrointestinal diarrhea outbreak. We investigated to identify the causative agent of the outbreak to support response operations. Methods: medical records were reviewed, and the daily line list was collected from health facilities. Descriptive data analysis was done by time, person and place. Stool specimens were first tested by antigen capture enzyme immunoassay (EIA) technique and further confirmed by reverse-transcription polymerase chain reaction (RT-PCR) as a gold standard. The product of RT-PCR was genotyped for each gene using G1-G4, G8-G9 and G12 primers for VP7 gene and P(4), P(6), P(8) and P(14) primers for VP4 gene. Results: a total of 1,987 diarrheal cases (5.7 per 1000) and five deaths (case-fatality rate 0.25%) were identified and epidemiologically-linked to confirmed rotavirus from December 2016 to February 2017. Among the cases, 1,946 (98%) were < 5 children. Fourteen (74%) of the 19 tested stool specimens were positive for rotavirus by EIA and RT-PCR. Majority of strains detected were G12P(6) (25%) and G-negative P(8) (25%) followed by G9P(8) (19%), G1P(8) (13%) and G3/G2 P(8), G12P(8), and G-negative P(6) (6% each). Conclusion: diarrheal outbreak which occurred in West-Shewa zone of Ethiopia was associated with rotavirus and relatively more affected districts with low vaccination coverage. Routine rotavirus vaccination quality and coverage should be evaluated and the surveillance system needs to be strengthened to detect, prevent and control a similar outbreak

Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial

Background: Schizophrenia is understood to be a heterogeneous brain condition with overlapping symptom dimensions. The negative symptom dimension, with its protean cognitive manifestations, responds poorly to treatment, which can be a particular challenge in countries where clozapine therapy is not available. Preliminary data indicate that minocycline may be beneficial adjunct in the treatment of schizophrenia: positive, negative, and cognitive symptoms. In this study we aim to assess the efficacy of adjunctive minocycline to alleviate symptoms of schizophrenia in patients who have failed to respond to a therapeutic trial of antipsychotic medications. Methods: The study is a parallel group, double-blind, randomized, placebo-controlled trial. Participants will be adults (aged 18 years and above) with first episode or relapse episode of schizophrenia of under 5 years’ duration. Patients who failed to show adequate therapeutic response to at least one antipsychotic medication given for a minimum of 4 weeks will be recruited from a psychiatry hospital in Addis Ababa and a psychiatry clinic in Butajira, Ethiopia. A total of 150 participants (75 in each arm) will be required to detect a five-point mean difference between the intervention arms adjusting for baseline symptom severity, at 90% power and 95% confidence. Patients in the intervention arm will receive minocycline (200 mg/day orally) added on to the regular antipsychotic medications participants are already on. Those in the placebo arm will receive an inactive compound identical in physical appearance to minocycline. Intervention will be offered for 12 weeks. Diagnosis will be established using the operational criteria for research (OPCRIT). Primary outcome measure will be a change in symptom severity measured using the positive and the negative syndrome scale for schizophrenia (PANSS). Secondary outcome measures will include changes in severity of negative symptoms, proportion achieving remission, and level of functioning. Whether changes are maintained post intervention will also be measured (PANSS). Key assessment for the primary outcome will be conducted at the end of trial (week 12). One post-intervention assessment will be conducted 4 weeks after the end of intervention (week 16) to determine sustainability of change. Trial registration Clinicaltrials.gov identifier: NCT01809158

FACTORS AFFECTING PHYSICIAN’S ADHERENCE TO GENERIC DRUG PRESCRIBING PRACTICE IN PRIVATE HEALTH FACILITIES, MEKELLE CITY, NORTHEASTERN ETHIOPIA

Introduction: Generic medicines are produced by multiple manufacturers hence, are usually cheaper than innovator brands and therefore save costs on medicines. Many physicians oppose brand substitution, believing generic medicines to be inferior to their originator counterparts. Physicians’ belief about generic medicines and factors affecting generic prescribing in Ethiopia are poorly investigated. Objective: To assess the physicians’ belief about generic medicines and to identify factors affecting generic medicines prescribing in private health facilities, Mekelle, Northern Ethiopia. Materials and Methods: An institution based cross-sectional study was conducted enrolling all physicians working in private health facilities. The data were collected from January 2016 to March 2016. Data were collected using self-administered structured questionnaires measuring generic medicines belief of physicians using a Likert scale of 1–5. Data were then entered into SPSS version 20 for analysis. Results: Of the fifty-six physicians approached in this study, 50 (89.2% response rate) questionnaires were included in the analysis. Nearly three-fourth (72%) of the physicians claimed that they always prescribe generic medicines. More than half (55.3) of the respondents beliefs generic medicines have different active ingredients than a brand innovator. Almost equal percentage (52% and 54%) of the Physicians disagreed with brand medicines were safer than generic medicines and prescribing generic due to the complicated health problem of the patient respectively. Around two third (67.5%) of physicians reported that quality profile of medicine was a major reason for prescribing generic medicines. Moreover, availability of medicines in pharmacies and low cost of medicines were the main reasons for prescribing generic medicines with 58.1% and 52.4% respectively. Conclusion: The majority of physicians do not have a positive perception of generic medicines and a significant portion of the physician’s belief brand medicines safer and effective than generic counterparts. The availability of medicines in pharmacies, low cost of medicines and purchasing power of the patients are major factors affecting generic medicines prescribing. Keywords: Generic medicines, belief, private health facilities, physiciansÂ